Reaction Biology 重新利用激酶抑製劑來治療 COVID-19

Reaction Biology 重新利用激酶抑製劑來治療 COVID-19

2021.06.04

 

本文轉載至原廠電子報: Reaction biology     https://www.reactionbiology.com/

原廠電子報

Reutilizing Kinase inhibitors: Drug screening identifies key kinase inhibitors exhibiting anti-SARS-CoV-2 activity. 

 

The ability of several small-molecule kinase inhibitors to modulate immune responses, as well as potentially block various stages in the SARS-CoV-2 life cycle, suggests they may have an important role in the emerging therapeutic arsenal. Screening kinase inhibitors against infected cell lines will not only help us discover alternative SARS-CoV-2 treatments but also help us understand the cell biology of the SARS-CoV-2. 

Read more about recent findings on repurposing kinase inhibitors to fight SARS-CoV-2 in our newest blog

 

 

Kinase inhibitor Berzosertib blocks replication of SARS-CoV-2 at a post-entry step. It may likely have several effects beyond inhibition of its primary target ATR kinase
(https://www.sciencedirect.com/science/article/pii/S2211124721002540)

 

Twitter

Facebook

Website

LinkedIn

 

 

 

 

 

back-Top
open-line

LINE 線上諮詢

亞旭-LINE-QRcode

掃瞄或手機直接點擊條碼

error: Content is protected !!